Reid Hoffman is leaving Microsoft’s board to go ‘founder mode’ with startup Manus
Quick Answer
Reid Hoffman is resigning from Microsoft's board after a decade to focus on his AI drug discovery startup, Manus.
Quick Take
This shift marks a significant transition for Hoffman, who aims to leverage his expertise in AI to innovate in the pharmaceutical sector.
Key Points
- Hoffman spent a profitable decade on Microsoft's board.
- He is now focusing on his startup Manus, specializing in AI drug discovery.
- This move highlights a trend of tech leaders returning to startup roots.
- Manus aims to innovate within the pharmaceutical industry using AI.
Source Excerpt
After a very profitable decade on Microsoft's board, Reid Hoffman is stepping down to focus on his AI drug discovery startup Manus.
Want this in your inbox every morning?
Daily brief at your local 8am — bilingual EN/中文, free.
More from TechCrunch
See more →
Why the first GPU financiers are turning to inference chips in a $400 million deal
General Compute secured a $400 million loan from Upper90, using inference-specific chips as collateral, signaling a shift towards cost-effective AI infrastructure. Their SN50 chips promise 16x faster inference than traditional GPU clouds, highlighting a growing market for open-source AI models and alternatives to Nvidia.
